NASDAQ · Medical - Diagnostics & Research

PSNL (PSNL) Stock

$13.52 +2.42% NASDAQ: PSNL Healthcare

Valuation

MetricValue
Price$13.52
Market Cap$1.44B
P/E Ratio-7.74
P/B Ratio2.40
P/S Ratio10.32
EPS (TTM)$-0.91
52-Week High$15.90
52-Week Low$3.84
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-31.03%
ROA-24.25%
ROCE-33.72%
Gross Margin13.72%
Operating Margin-1.59%
Net Margin-1.48%
Debt/Equity0.12
Current Ratio6.70

Annual Financials (USD)

Metric20212022202320242025
Revenue$85.0M$65.0M$73.0M$85.0M$0
Operating Profit$-65.0M$-116.0M$-110.0M$-68.0M$-88.0M
Net Profit$-65.0M$-113.0M$-108.0M$-81.0M$-81.0M
EPS$-1.49$-2.48$-2.25$-1.37$-0.91
Op Margin-76.4%-177.6%-149.6%-80.7%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$397.0M$293.0M$225.0M$270.0M$334.0M
Total Liabilities$86.0M$75.0M$96.0M$67.0M$73.0M
Cash$106.0M$89.0M$57.0M$91.0M$124.0M
Borrowings$58.0M$49.0M$48.0M$44.0M$32.0M

Latest News

Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In Simply Wall St. · Jul 22, 2026 Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion Quartz · Jul 21, 2026 Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal Medical Device Network · Jul 21, 2026 Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring Simply Wall St. · Jul 21, 2026 Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal GuruFocus.com · Jul 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-71.0M$-70.0M$-56.0M$-45.0M$-75.0M
Investing Cash Flow$-71.0M$3.0M$2.0M$-37.0M$-27.0M
Financing Cash Flow$4.0M$2.0M$7.0M$18.0M$0
Net Cash Flow$39.0M$-16.0M$-32.0M$34.0M$33.0M
Free Cash Flow$-82.0M$-120.0M$-67.0M$-47.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-12.71%
Quick Ratio6.44
Interest Coverage—
Return 1Y80.77%
Return 3Y465.74%
Return 5Y-28.43%

Ownership

Insiders Held26.16%
Institutions Held66.94%
Institutions Float Held90.66%
Institutional HolderSharesReport Date
Merck & Co., Inc.14,044,9432026-03-31
Lightspeed Management Company, L.L.C. 8,160,7342026-03-31
ARK Investment Management, LLC7,944,1122026-03-31
Ameriprise Financial, Inc.7,592,8072026-03-31
Blackrock Inc.5,389,8852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BFLY $8.28 -1.72% -60.65 $2.20B 0.00%
CDNA $43.71 +14.72% 18.87 $2.26B 0.00%
CSTL $24.44 -0.99% -23.63 $741.26M 0.00%
EVH $3.04 -4.56% -0.77 $341.38M 0.00%
FLGT $18.53 -0.11% -8.10 $526.26M 0.00%

About PSNL

PSNL is led by CEO Christopher Hall, employs 228 people, headquartered in US, publicly traded since 2019.

PSNL stock trades at $13.52 with a market capitalization of $1.44B. The stock is valued at a price-to-earnings (P/E) ratio of -7.74, price-to-book of 2.40, price-to-sales of 10.32. Over the past 52 weeks the stock has ranged between $3.84 and $15.90, and currently trades 15.0% below its 52-week high.

On profitability, PSNL generates a return on equity (ROE) of -31.03%, return on capital employed of -33.72%, an operating margin of -1.59%, a net profit margin of -1.48%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides